VAD Regimen as Initial Treatment for Multiple Myeloma

VAD Regimen as Initial Treatment for Multiple Myeloma

Show other versions (1)

"nIntroduction: The aim of our study is evaluation of response rate of VAD (Vincristin, Adriamycin and Dexamethason) regimen as initial treatment in 40 new cases of multiple myeloma. This is the first systemic and classic report of VAD regimen in Iranian population. "nMethods: All...

Full description

Bibliographic Details
Main Authors:	Mohammad Ali Mashhadi, Mehdi Hashemi, Negin Khosravi
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2010-10-01
Series:	International Journal of Hematology-Oncology and Stem Cell Research
Subjects:	VAD regimen Initial therapy Multiple myeloma
Online Access:	http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/18882.pdf&manuscript_id=18882

Similar Items

VAD Regimen as Initial Treatment for Multiple Myeloma
by: Mohammad Ali Mashhadi, et al.
Published: (2010-12-01)

VAD Chemotherapy Versus Bortezomib Containing Regimens As Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
by: Aysun Senturk Yikilmaz, et al.
Published: (2020-10-01)

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

Multiple myeloma: challenges with deciding the optimal sequencing strategy
by: Anushka Walia, et al.
Published: (2023-07-01)

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment
by: Shiyuan Zhou, et al.
Published: (2023-09-01)

Editorial: Hemostasis in ECMO and VAD, volume II
by: Jun Teruya, et al.
Published: (2023-07-01)

THE EFFECT OF MULTIDRUG RESISTANCE GENE EXPRESSION ON THE CLINICAL COURSE OF MULTIPLE MYELOMA
by: Yu. B. Chernykh, et al.
Published: (2017-01-01)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
by: Ga-Young Song, et al.
Published: (2022-08-01)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
by: Jingsong He, et al.
Published: (2020-12-01)

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM
by: Friederike Bachmann, et al.
Published: (2021-03-01)

Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation
by: Lixin Gong, et al.
Published: (2024-01-01)

CURRENT DEVELOPMENTS AND PERSPECTIVES IN MULTIPLE MYELOMA
by: Michel Delforge, et al.
Published: (2014-07-01)

Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
by: Luo XW, et al.
Published: (2018-08-01)

HiVAD : A Voice Activity Detection Application Based on Deep Learning
by: MUHAMMAD HILMI FARIDH, et al.
Published: (2021-10-01)

Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma
by: Ane Amundarain, et al.
Published: (2022-11-01)

Thalidomide and its analogues in the treatment of Multiple Myeloma
by: Latif Tahir, et al.
Published: (2012-09-01)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01)

Multiple Myeloma Therapy: Emerging Trends and Challenges
by: Danai Dima, et al.
Published: (2022-08-01)

How to Diagnose, Treat, and Monitor Treatment Response in Patients with Multiple Myeloma
by: Wulyo Rajabto, et al.
Published: (2022-07-01)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
by: Katja Weisel, et al.
Published: (2020-08-01)

Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter studyResearch in context
by: Li Bao, et al.
Published: (2024-02-01)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
by: Norbert Grzasko, et al.
Published: (2021-11-01)

CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts
by: Michael J. VanWyngarden, et al.
Published: (2023-11-01)

Chromosomal aberrations in multiple myeloma: A study on Indian population
by: Angel Beula P. Royal, et al.
Published: (2018-01-01)

Emerging agents and regimens for multiple myeloma
by: Yang Yang, et al.
Published: (2020-11-01)

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
by: J Picot, et al.
Published: (2011-12-01)

Anaplastic morphology in IgD multiple myeloma
by: Verónica Roldán Galiacho, et al.
Published: (2023-10-01)

Immunotherapy for the treatment of multiple myeloma
by: Leora S. Boussi, et al.
Published: (2022-10-01)

Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
by: Denisa Weiser Drozdkova, et al.
Published: (2021-06-01)

Prognostic and predictive biomarker developments in multiple myeloma
by: Craig T. Wallington-Beddoe, et al.
Published: (2021-09-01)

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy
by: Charlotte F. M. Hughes, et al.
Published: (2024-03-01)

How to Optimize ECLS Results beyond Ventricular Unloading: From ECMO to CentriMag<sup>®</sup> eVAD
by: Vincenzo Tarzia, et al.
Published: (2022-08-01)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
by: Muhamed Baljevic, et al.
Published: (2022-11-01)

Pseudohypercalcemia in Multiple Myeloma: A Case Report
by: Farzaneh Ashrafi, et al.
Published: (2016-07-01)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011-12-01)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011-12-01)

Evaluation of Emotions from Brain Signals on 3D VAD Space via Artificial Intelligence Techniques
by: Ümran Işık, et al.
Published: (2023-06-01)

MANDİBULADA MULTİPL MYELOMA İKİ OLGU SUNUMU
by: Hümeyra Kocaelli
Published: (2005-05-01)

Multiple myeloma and kidney disease
by: Natalia Zarankiewicz, et al.
Published: (2022-08-01)

Multiple Myeloma: An Update
by: Khalil Al-Farsi
Published: (2013-01-01)